Skip to main content

Douglas Johnson Archives

Several from VUMC among most highly cited researchers

Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

Nov. 16, 2022—Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.

Read more


Directorships honor VUMC leaders and philanthropic partners

Sep. 8, 2022—by Doug Campbell Last week, Vanderbilt University Medical Center held a Directorship Celebration to honor 21 leaders from across the enterprise in clinical care, research, education and administration. “Endowed directorships support the excellence of our leading physicians and scientists,” said Jeff Balser, MD, PhD, CEO of VUMC and Dean of Vanderbilt University School of Medicine....

Read more


Abramson, Eng, Johnson named to new VICC roles

Aug. 18, 2022—Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

Read more


Directorships honor VUMC leaders and philanthropic partners

Dec. 2, 2021—Ten Vanderbilt University Medical Center leaders from across the enterprise in clinical care, research, education and administration have been named as holders of endowed directorships.

Read more


Seven from VUMC among most highly cited researchers

Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


Forty-three percent of melanoma patients have chronic complications from immunotherapies

Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Read more


Study identifies targeted therapy’s cardiac risks

Sep. 25, 2019—After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Read more


Encephalitis identified as rare toxicity of immunotherapy treatment

Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Read more


Medical Societies honor multiple Vanderbilt faculty

Apr. 18, 2019—Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).

Read more


Immunotherapies linked to specific heart complications

Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

Read more


Study tracks incidence, timing of immunotherapy-related deaths

Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more